These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 38378856)
1. Immunogenicity and protective efficacy of a co-formulated two-in-one inactivated whole virus particle COVID-19/influenza vaccine. Handabile C; Ohno M; Sekiya T; Nomura N; Kawakita T; Kawahara M; Endo M; Nishimura T; Okumura M; Toba S; Sasaki M; Orba Y; Chua BY; Rowntree LC; Nguyen THO; Shingai M; Sato A; Sawa H; Ogasawara K; Kedzierska K; Kida H Sci Rep; 2024 Feb; 14(1):4204. PubMed ID: 38378856 [TBL] [Abstract][Full Text] [Related]
2. Inactivated whole virus particle vaccine with potent immunogenicity and limited IL-6 induction is ideal for influenza. Sekiya T; Mifsud EJ; Ohno M; Nomura N; Sasada M; Fujikura D; Daito T; Shingai M; Ohara Y; Nishimura T; Endo M; Mitsumata R; Ikeda T; Hatanaka H; Kitayama H; Motokawa K; Sobue T; Suzuki S; Itoh Y; Brown LE; Ogasawara K; Kino Y; Kida H Vaccine; 2019 Apr; 37(15):2158-2166. PubMed ID: 30857932 [TBL] [Abstract][Full Text] [Related]
3. Immunization with inactivated whole virus particle influenza virus vaccines improves the humoral response landscape in cynomolgus macaques. Chua BY; Sekiya T; Koutsakos M; Nomura N; Rowntree LC; Nguyen THO; McQuilten HA; Ohno M; Ohara Y; Nishimura T; Endo M; Itoh Y; Habel JR; Selva KJ; Wheatley AK; Wines BD; Hogarth PM; Kent SJ; Chung AW; Jackson DC; Brown LE; Shingai M; Kedzierska K; Kida H PLoS Pathog; 2022 Oct; 18(10):e1010891. PubMed ID: 36206307 [TBL] [Abstract][Full Text] [Related]
4. Flu-COVID combo recombinant protein vaccines elicited protective immune responses against both influenza and SARS-CoV-2 viruses infection. Huang Y; Shi H; Forgacs D; Ross TM Vaccine; 2024 Feb; 42(5):1184-1192. PubMed ID: 38296701 [TBL] [Abstract][Full Text] [Related]
5. Inactivated Whole Virus Particle Influenza Vaccine Induces Anti-Neuraminidase Antibodies That May Contribute to Cross-Protection against Heterologous Virus Infection. Handabile C; Sekiya T; Nomura N; Ohno M; Kawakita T; Shingai M; Kida H Vaccines (Basel); 2022 May; 10(5):. PubMed ID: 35632561 [TBL] [Abstract][Full Text] [Related]
6. A SARS-CoV-2 and influenza double hit vaccine based on RBD-conjugated inactivated influenza A virus. Wang Z; Li Z; Shi W; Zhu D; Hu S; Dinh PC; Cheng K Sci Adv; 2023 Jun; 9(25):eabo4100. PubMed ID: 37352360 [TBL] [Abstract][Full Text] [Related]
7. Obesity Is Associated with an Impaired Baseline Repertoire of Anti-Influenza Virus Antibodies. Abd Alhadi M; Friedman LM; Karlsson EA; Cohen-Lavi L; Burkovitz A; Schultz-Cherry S; Noah TL; Weir SS; Shulman LM; Beck MA; Hertz T Microbiol Spectr; 2023 Jun; 11(3):e0001023. PubMed ID: 37098954 [TBL] [Abstract][Full Text] [Related]
8. Safety and immunogenicity of a high-dose quadrivalent influenza vaccine administered concomitantly with a third dose of the mRNA-1273 SARS-CoV-2 vaccine in adults aged ≥65 years: a phase 2, randomised, open-label study. Izikson R; Brune D; Bolduc JS; Bourron P; Fournier M; Moore TM; Pandey A; Perez L; Sater N; Shrestha A; Wague S; Samson SI Lancet Respir Med; 2022 Apr; 10(4):392-402. PubMed ID: 35114141 [TBL] [Abstract][Full Text] [Related]
9. Rationale for vaccination with trivalent or quadrivalent live attenuated influenza vaccines: Protective vaccine efficacy in the ferret model. Rudenko L; Kiseleva I; Krutikova E; Stepanova E; Rekstin A; Donina S; Pisareva M; Grigorieva E; Kryshen K; Muzhikyan A; Makarova M; Sparrow EG; Torelli G; Kieny MP PLoS One; 2018; 13(12):e0208028. PubMed ID: 30507951 [TBL] [Abstract][Full Text] [Related]
10. Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine (Sinopharm BBIBP-CorV) coadministered with quadrivalent split-virion inactivated influenza vaccine and 23-valent pneumococcal polysaccharide vaccine in China: A multicentre, non-inferiority, open-label, randomised, controlled, phase 4 trial. Chen H; Huang Z; Chang S; Hu M; Lu Q; Zhang Y; Wang H; Xiao Y; Wang H; Ge Y; Zou Y; Cui F; Han S; Zhang M; Wang S; Zhu X; Zhang B; Li Z; Ren J; Chen X; Ma R; Zhang L; Guo X; Luo L; Sun X; Yang X Vaccine; 2022 Aug; 40(36):5322-5332. PubMed ID: 35931636 [TBL] [Abstract][Full Text] [Related]
11. A combination vaccine against SARS-CoV-2 and H1N1 influenza based on receptor binding domain trimerized by six-helix bundle fusion core. Shi R; Zeng J; Xu L; Wang F; Duan X; Wang Y; Wu Z; Yu D; Huang Q; Yao YG; Yan J EBioMedicine; 2022 Nov; 85():104297. PubMed ID: 36206623 [TBL] [Abstract][Full Text] [Related]
12. Potent priming by inactivated whole influenza virus particle vaccines is linked to viral RNA uptake into antigen presenting cells. Shingai M; Nomura N; Sekiya T; Ohno M; Fujikura D; Handabile C; Omori R; Ohara Y; Nishimura T; Endo M; Kimachi K; Mitsumata R; Ikeda T; Kitayama H; Hatanaka H; Sobue T; Muro F; Suzuki S; Thanh Nguyen C; Ishigaki H; Nakayama M; Mori Y; Itoh Y; Koutsakos M; Chua BY; Kedzierska K; Brown LE; Jackson DC; Ogasawara K; Kino Y; Kida H Vaccine; 2021 Jun; 39(29):3940-3951. PubMed ID: 34090697 [TBL] [Abstract][Full Text] [Related]
13. [Technical guidelines for seasonal influenza vaccination in China (2023-2024)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG), Influenza Vaccination TWG Zhonghua Liu Xing Bing Xue Za Zhi; 2023 Oct; 44(10):1507-1530. PubMed ID: 37875437 [TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 and Influenza A Virus Coinfections in Ferrets. Huang Y; Skarlupka AL; Jang H; Blas-Machado U; Holladay N; Hogan RJ; Ross TM J Virol; 2022 Mar; 96(5):e0179121. PubMed ID: 34936487 [TBL] [Abstract][Full Text] [Related]
15. A Recombinant VSV-Based Bivalent Vaccine Effectively Protects against Both SARS-CoV-2 and Influenza A Virus Infection. Ao Z; Ouyang MJ; Olukitibi TA; Warner B; Vendramelli R; Truong T; Meilleur C; Zhang M; Kung S; Fowke KR; Kobasa D; Yao X J Virol; 2022 Sep; 96(18):e0133722. PubMed ID: 36069551 [TBL] [Abstract][Full Text] [Related]
16. A subunit-based influenza/SARS-CoV-2 Omicron combined vaccine induced potent protective immunity in BALB/c mice. Zhang N; Ye Z; Li C; Zhou J; Xue W; Xiang L; Chen Y; Chen S; Ye R; Dong J; Zhou J; Jiang S; Han H J Med Virol; 2024 Mar; 96(3):e29479. PubMed ID: 38425270 [TBL] [Abstract][Full Text] [Related]
17. [Technical guidelines for seasonal influenza vaccination in China (2022-2023)]. National Immunization Advisory Committee (NIAC) Technical Working Group (TWG) on Influenza Vaccination Zhonghua Yu Fang Yi Xue Za Zhi; 2022 Oct; 56(10):1356-1386. PubMed ID: 36274602 [TBL] [Abstract][Full Text] [Related]
18. Inactivated H7 Influenza Virus Vaccines Protect Mice despite Inducing Only Low Levels of Neutralizing Antibodies. Kamal RP; Blanchfield K; Belser JA; Music N; Tzeng WP; Holiday C; Burroughs A; Sun X; Maines TR; Levine MZ; York IA J Virol; 2017 Oct; 91(20):. PubMed ID: 28768855 [TBL] [Abstract][Full Text] [Related]